Stephen M. Dunn

In a report published Monday, LifeTech Capital analyst Stephen M. Dunn reiterated a Neutral rating on Echo Therapeutics (NASDAQ: ECTE). In the report, LifeTech Capital noted, “Maintaining Neutral Rating: We continue to believe Echo's Symphony tCGM remains a world-class technology trapped under a...

In a report published Monday, LifeTech Capital analyst Stephen M. Dunn downgraded the rating on Echo Therapeutics (NASDAQ: ECTE) from Strong Speculative Buy to Neutral, and removed the $3.75 price target. In the report, LifeTech Capital noted, “Echo announced a $12M capital raise at $2.70 ($0....